Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VRDN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsViridian receives FDA approval for Lumvoa, first TED therapy covering active and chronic disease
Filed June 29, 2026 · Period ending June 26, 2026 · ~1 min read
Key Changes
-
high
FDA approved Lumvoa for thyroid eye disease treatment regardless of activity or duration, making it the first approved TED therapy with labeling covering both active and chronic disease forms.
Item 8.01 — Other Events verify on EDGAR → -
high
Viridian launching Lumvoa immediately with prescriptions available next day; marks company's transition from development to commercial stage.
Exhibit 99.1 view on EDGAR → -
high
Pivotal THRIVE trials met all primary and secondary endpoints with clinical benefits appearing as early as three weeks; Lumvoa first approved TED product showing statistically significant effects on diplopia in both active and chronic disease.
Exhibit 99.1 view on EDGAR → -
medium
Safety profile includes infusion reactions in 9% of patients, hyperglycemia in 12%, and potential severe hearing impairment that may be permanent; most common adverse reactions include muscle spasms, headache, and fatigue.
Exhibit 99.1 view on EDGAR → -
medium
Subcutaneous elegrobart remains on track for BLA submission in Q1 2027, representing second potential TED product in pipeline.
Exhibit 99.1 view on EDGAR →
Summary
Viridian Therapeutics received FDA approval for Lumvoa (veligrotug-vvze) to treat thyroid eye disease regardless of disease activity or duration, a significant regulatory milestone that positions the drug as the first approved TED therapy with labeling covering both active and chronic forms of the disease.
The company is launching immediately, with prescriptions available the next day, marking its transition from a development-stage to commercial-stage biotech.
The approval was supported by two pivotal Phase 3 trials (THRIVE and THRIVE-2) that met all primary and secondary endpoints, demonstrating statistically significant improvements in TED signs and symptoms by week 15, with clinical benefits appearing as early as three weeks. For investors, this represents the beginning of potential revenue generation, though actual sales will depend on manufacturing scale-up, payer coverage decisions, and market adoption against existing TED therapies. The broad labeling covering both active and chronic disease may provide a competitive advantage. The safety profile includes notable warnings: infusion reactions in 9% of patients, hyperglycemia in 12%, and potential permanent hearing impairment. Viridian has established ViridianCares for patient support and financial assistance. The company's pipeline includes subcutaneous elegrobart, on track for BLA submission in Q1 2027, which could offer improved convenience for TED patients.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · verify on EDGAR →
the U.S. Food and Drug Administration (FDA) has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED)
Viridian received FDA approval for Lumvoa, its first commercial product, to treat thyroid eye disease. Lumvoa is the first approved TED treatment with labeling covering both active and chronic disease. The approval was granted under Priority Review and Breakthrough Therapy Designation, supported by two pivotal phase 3 trials (THRIVE and THRIVE-2) that met all primary and secondary endpoints.
Added in current filing · verify on EDGAR →
Viridian plans to launch Lumvoa immediately, and physicians can prescribe Lumvoa tomorrow
The company is launching Lumvoa immediately following FDA approval, with prescriptions available starting the next day. Viridian has established ViridianCares, a patient support program providing insurance coverage support, benefit verification, and financial assistance for eligible patients. This marks Viridian's transition from a development-stage to a commercial-stage company.
Added in current filing · view on EDGAR →
subcutaneous elegrobart on track for a biologics license application (BLA) submission in Q1 2027
Viridian confirmed that elegrobart, a subcutaneous therapy for TED designed to improve patient convenience, remains on track for a BLA submission in Q1 2027. This represents the company's second potential TED product following Lumvoa's approval.
Added in current filing · view on EDGAR → · paraphrased
Infusion reactions have been reported in approximately 9% of patients treated with Lumvoa. Signs and symptoms of infusion-related reactions include transient increases in blood pressure, fever, chills, headache, and fatigue. In clinical trials, 12% of patients, of whom one-half had preexisting diabetes or impaired glucose tolerance, experienced hyperglycemia. Lumvoa may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Most common adverse reactions (incidence of 5% or more) are muscle spasms, headache, hearing impairment, hyperglycemia, fatigue, diarrhea, ear discomfort, infusion-related reaction, nausea, nasopharyngitis, blood creatine phosphokinase increased, dry skin, and hypertension.
The approved labeling includes warnings for infusion reactions (9% of patients), hyperglycemia (12% of patients, half with preexisting diabetes/glucose intolerance), potential inflammatory bowel disease exacerbation, and severe hearing impairment that may be permanent. Common adverse reactions occurring in 5% or more of patients include muscle spasms, headache, hearing impairment, hyperglycemia, and fatigue among others. Patients require monitoring before, during, and after treatment.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Viridian plans to launch Lumvoa immediately.
The company intends to commercialize Lumvoa without delay following FDA approval. An immediate launch means revenue generation could begin in the current quarter, though actual sales will depend on manufacturing readiness, distribution agreements, payer coverage, and market adoption.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
the U.S. Food and Drug Administration (the “FDA”) has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (“TED”) regardless of activity or duration
The FDA has approved the company's drug Lumvoa (veligrotug-vvze) for treating thyroid eye disease without restrictions on disease activity or duration. This is a major regulatory milestone that allows the company to commercialize its lead product in the U.S. market for all TED patients, not just a subset defined by disease stage.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 30, 2026 · How we verify